Summer 2015: Diakonos founded

Winter 2015: Diakonos Licenses Initial Intellectual Property From Baylor College of Medicine, Houston, Tx. (Link)

Spring 2016: Breakthrough Publication: Diakonos partner scientists publish a groundbreaking paper regarding novel functionality of dendritic cells and the immune system. (Link)

Spring 2016: New Technology: Diakonos partner scientists develop a new technology regarding dendritic cell CTLA-4 function, resulting in new intellectual property

Spring 2016: Press Release: Baylor College of Medicine issues press release concerning the importance of this fundamental discovery (Link)

Spring 2016: IP LicensureDiakonos successfully licenses this additional intellectual property, adding to its growing portfolio.

Spring 2016: Breakthrough Publication: Diakonos partner scientists publish a  proof-of-principle study demonstrating the power of Diakonos technology in a difficult-to-treat preclinical cancer model. (Link)

Summer 2017: Breakthrough Publication: Diakonos partner scientists publish on a newly developed technology involving the use of dendritic cells for the treatment of Chagas Disease (Link)

Fall 2017: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to its growing portfolio.

Winter 2017: New Technology: Diakonos partner scientists develop a new technology regarding amplification of tumor antigenic preparations. This breakthrough technology allows cancer immunotherapy to proceed using very small numbers of patient tumor cells.

Spring 2018: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to its growing portfolio.

Early 2018: Breakthrough Publication: Diakonos partner scientists publish a critical mechanistic study demonstrating robustness and uniqueness of the Diakonos therapeutic process. (Link)

Spring 2018: External Licensing Deal: Diakonos and APAC Biotech of Gurgaon, India agree to licensing deal re: APAC's use of patented Diakonos technologies (Link)

Spring 2018: First human treatment with Diakonos Technology - First cancer patients treated in India with Diakonos technology, demonstrating safety and feasibility of the approach.

Summer 2018: Investigators using Diakonos technology receive FDA regulatory clearance for a Phase I clinical trial of resectable pancreatic cancer (PDAC).

Summer 2019: Investigators using Diakonos receive FDA regulatory clearance for a Phase I clinical trial of newly-diagnosed or relapsed GBM

Summer 2019: Press Release: re: GBM trial and approvals (Link)

Summer 2019: Breakthrough Publication: Diakonos partner scientists publish results of canine splenic hemangiosarcoma trial using Diakonos vaccine technology. (Link)

Fall 2019: New Technology: Diakonos partner scientists patent ground-breaking novel CAR T-cell platform.

Winter 2019: IP LicensureDiakonos successfully licenses this additional intellectual property, adding to its expanding portfolio.

Spring 2020: Breakthrough Publication: Diakonos partner scientists publish groundbreaking study outlining in sophisticated detail the mechanism by which Diakonos technology functions. (Link)

Summer 2020: CLINICAL TRIALIn combination with Baylor College of Medicine and Cancer Cures 4 Kids, a clinical trial using technology licensed to Diakonos opens. Known as DECIST (Dendritic Cell Immunotherapy plus Standard Care for the Adjuvant Treatment of PDAC), the study is open and accruing at Baylor/St. Luke's Medical Center in Houston. (Link)

Diakonos Research Ltd.

1110 Nasa Parkway Suite 108i

Houston, TX 77058

©2016 BY DIAKONOS RESEARCH LTD.

832-746-3427